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Abstract
Progress toward a highly convergent, asymmetric synthesis of brevenal is reported. Construction of
the AB-ring and E-ring cyclic ether fragments was achieved through asymmetric alkylation/ring-
closing metathesis strategies. A Horner-Wadsworth-Emmons olefination was used in a key bond-
forming step to couple the advanced cyclic fragments and enable rapid access to the AB-E ring
system.
Marine polycyclic ether natural products have received much attention over the years due to
their unique and highly complex molecular architecture, in addition to their diverse and potent
biological activities.1 A number of bioactive polyether natural products have been isolated
from the marine dinoflagellate Karenia brevis, the organism responsible for toxic red tides
along Florida's Gulf Coast. The most well-known compounds isolated from K. brevis are a
family of neurotoxins called the brevetoxins. The brevetoxins are responsible for massive kills
of fish and marine animals and can also adversely affect humans; inhaled brevetoxins cause
respiratory irritation and breathing difficulties in sensitive populations.2 At high
concentrations, ingested brevetoxins lead to a collection of symptoms commonly referred to
as neurotoxic shellfish poisoning (NSP).3 Brevenal (1) was isolated in 2004 from K. brevis
and has been shown to counteract the toxic effects of the brevetoxins.4 Specifically, brevenal
has been shown to competitively displace titrated dihydrobrevetoxin-B from voltage sensitive
sodium channels in rat brain synaptosomes in a dose-dependent manner, alleviating the toxic
effects of the brevetoxins in vivo.5 More importantly, picomolar concentrations of brevenal
were found to increase tracheal mucus velocity to the same degree as that observed with
millimolar concentrations of a sodium channel blocker, amiloride, which is used in the
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treatment of the debilitating lung disorder cystic fibrosis.6 As such, brevenal represents a
potential lead for the development of novel therapeutic agents for the treatment of mucociliary
dysfunction associated with cystic fibrosis and other lung disorders. To date, two syntheses of
brevenal have been reported by the laboratories of Sasaki7 and Yamamoto.8
Our retrosynthetic analysis of brevenal includes the installation of the unsaturated side chains
at both ends of the molecule late in the synthesis (Scheme 1). The pentacyclic polyether core
was envisioned to arise from advanced enone 3 via an acid-catalyzed cyclodehydration to form
the D-ring (2) followed by cyclization to afford the C-ring. Enone 3 would be made available
through a Horner-Wadsworth-Emmons coupling between AB-ring β-ketophosphonate 4 and
E-ring aldehyde 5.
Initial efforts toward the total synthesis of brevenal focused on the construction of AB-ring β-
ketophosphonate 4. The retrosynthesis of 4 is centered on a glycolate alkylation/ring-closing
metathesis approach, developed in our laboratory, for the enantioselective construction of
medium-ring ethers (Scheme 2).9 It was envisioned that the β-ketophosphonate functionality
would be installed in three steps from nitrile 6. Access to the 6,7-fused system would hinge on
closure of the medium-ring ether via a ring-closing metathesis reaction of diene 7.
Stereoselective alkylation of glycolate 8 followed by conversion of the oxazolidinone to the
olefin would afford advanced diene 7. The precursor to glycolate 8, enol ether 9, would be
accessed from 10 via a cyclodehydration reaction. A Horner-Wadsworth-Emmons coupling of
aldehyde 11 and β-ketophosphonate 12 would give rise to 10.
The synthesis commenced with a monobenzylation of commercially available 1,4-
butanediol10 (13) followed by a Jones’ oxidation11 to afford carboxylic acid 14 (Scheme 3).
Conversion to the methyl ester under acidic conditions followed by displacement with
lithiodimethyl methylphosphonate12 then furnished β-ketophosphonate 12 in excellent yield
over the four steps. The preparation of aldehyde 11 began with a highly diastereoselective
“Evans” syn propionate aldol addition13 between phenylalanine-derived N-
propionylthiazolidinethione 15 and aldehyde 16. The resultant aldol adduct 17 was protected
as the trimethylsilyl (TMS) ether, and reductive removal of the auxiliary furnished the desired
aldehyde 11.
With both aldehyde 11 and β-ketophosphonate 12 prepared, efforts were directed toward the
completion of the AB-ring fragment. Enone 10 was prepared in 90% yield under mild reaction
conditions using a modified Horner-Wadsworth-Emmons olefination.14 1,4-reduction of
1015 followed by deprotection of the TMS group generated hydroxy ketone 18. After screening
a variety of cyclodehydration conditions, it was discovered that camphorsulfonic acid (CSA)
in the presence of molecular sieves afforded enol ether 9 in excellent yield. Enol ether 9 was
then transformed to thioacetal 19 via an epoxide intermediate,16 and the resulting hydroxyl
group was protected as the triethylsilyl (TES) ether. The thioethyl group was converted to a
methyl group in onepot, using Sasaki's protocol, to give pyran 20.17 It was found that protection
of the hydroxyl group was necessary for this reaction to proceed in high yield.
With the necessary A-ring functionality in place, construction of the B-ring then ensued. The
benzyl group was cleaved in the presence of sodium naphthalenide18 to generate alcohol 21.
Swern oxidation19 of the resultant hydroxyl group, followed by a methylene Wittig reaction,
20 afforded olefin 22. The TES ether was then cleaved with CSA and ethanol to give alcohol
23. At this point, our glycolate alkylation/ring-closing metathesis strategy was applied to
construct the seven-membered B-ring. Alcohol 23 was transformed to the glycolic acid in the
presence of sodium hydride and bromoacetic acid. In one pot, the resultant acid was converted
to the mixed pivalic anhydride and treated in situ with the lithium salt of (R)-4-isopropyl-2-
oxazolidinone to produce acyl oxazolidinone 8. Treatment of the sodium enolate of 8 with
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bromoacetonitrile resulted in a highly diastereo-selective glycolate alkylation21 to furnish the
nitrile. The modest yield associated with this reaction is attributed to the formation of an
unidentifiable byproduct formed during the enolization process. All attempts to optimize this
reaction, however, were unsuccessful. The oxazolidinone was then reductively cleaved to
reveal alcohol 25. Oxidation of 25 to the aldehyde under Swern conditions occurred in high
yield. Initially, the resulting aldehyde was subjected to a methylene Wittig reaction using an
ylide generated in situ from potassium t-butoxide and methyltriphenylphosphonium bromide.
The presence of the nitrile, however, facilitated an elimination reaction under these rather basic
conditions, thus regenerating alcohol 23. To circumvent this undesired elimination, the
methylenation reaction was performed using crystallized, salt-free methylene
triphenylphosphorane, thereby giving rise to the desired diene 7.22 B-Ring formation was
achieved upon exposure of 7 to Grubbs’ second generation catalyst,23 affording bicycle 26 in
94%. Dihydroxylation of the resultant olefin occurred readily to furnish the desired diol as a
single diastereomer. Subsequent protection of the diol afforded advanced acetonide 6.
Diisobutylaluminum hydride easily reduced the nitrile to the aldehyde. In two steps, 6 was
converted to β-ketophosphonate 4 to complete the AB-ring fragment with 27 steps in the
longest linear sequence. The stereochemistry was confirmed by nOESY analysis.
With the AB-ring β-ketophosphonate in hand, efforts then focused on the synthesis of the E-
ring aldehyde (5, Scheme 4). An asymmetric aldol addition, originally reported by Kobayashi
and coworkers,24 between oxazolidinone 27 and aldehyde 28 was used to prepare aldol adduct
29. The auxiliary was converted to the methyl ester and the free hydroxyl group was protected
as the TES ether to give ester 30. Conversion of 30 to aldehyde 31 was carried out using a two
step reduction-oxidation sequence. After generation of a terminal olefin from the aldehyde
functionality through a Wittig reaction, the TES group was removed to furnish alcohol 32.
Alkylation of 32 with bromoacetic acid followed by coupling with a valine-derived
oxazolidinone enabled isolation of glycoyl oxazolidinone 34. Generation of the sodium enolate
of 34 followed by alkylation with bromoacetonitrile introduced the third stereogenic center
with excellent diastereoselectivity (95:5 dr). Reductive removal of the auxiliary then furnished
alcohol 35, and the resultant hydroxyl group was easily oxidized to aldehyde 36 under Swern
conditions. Treatment of 36 with divinyl zinc installed the second olefin as a mixture of
diastereomers (37). Exposure of this diastereomeric mixture to Grubbs’ second generation
catalyst enabled the isolation of cyclic ethers 38 and 39. The undesired diastereomer 38 could
be converted to 39 via a two step oxidation/reduction sequence. Protection of 39 as a TES ether
and reduction of the nitrile generated E-ring aldehyde 5 in 16 steps from 27.
With both the AB-ring β-ketophosphonate and E-ring aldehyde prepared, attention was
directed toward coupling of the fragments and completing brevenal (Scheme 5). β-
Ketophosphonate 4 and aldehyde 5 were joined through a barium hydroxide-mediated Horner-
Wadsworth-Emmons reaction to provide advanced enone 3 in excellent yield. In order to
complete the total synthesis of brevenal, we envision the closure of the D-ring via an acid-
catalyzed cyclodehydration. Manipulation of the resulting enol ether (2) to give ketone 40
followed by formation of the C-ring via acetalization will give the pentacyclic polyether core
(41). Installation of the left- and right-hand side chains will then furnish brevenal (1).
In summary, a highly convergent approach toward the total synthesis of brevenal has been
reported. Two key cyclic ether fragments have been constructed utilizing our asymmetric
glycolate alkylation/ring-closing metathesis approach. Fragment coupling has been carried out
in excellent yield and efforts to complete the carbon framework and elaborate the side chains
are ongoing.
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Retrosynthetic plan for β-ketophosphonate 4.
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Synthesis of AB-ring β-ketophosphonate 4.
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Synthesis of aldehyde 5.
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Coupling of the fragments and proposed endgame.
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